UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Amendment No. 1
to SCHEDULE 13D

Under the Securities Exchange Act of 1934

MOUNTAIN HIGH ACQUISITIONS CORP.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

62405W100

(CUSIP Number)

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

April 23, 2020

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box: ¨

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

*Dr. Pham is the sole member and manager of the reporting persons, Alchemy Capital LLC and Trilogy Capital LLC.

This report on Schedule 13D (this “Report”) pertains to the common stock, par value $0.0001 per share, of Mountain High Acquisitions Corp., a Colorado corporation (the “Company” or the “Issuer”). The Issuer’s principal executive offices are located at 6501 E. Greenway Parkway #103-412, Scottsdale, Arizona 85254.

This Report is being filed on behalf of Dr. Judy Pham, Trilogy Capital, LLC, and Alchemy Capital, LLC (collectively, the “Reporting Persons”).

The address of the Reporting Persons is 578 Washington Blvd., Suite 578, Marina del Rey, CA 90292.

Dr. Pham’s principal occupation is as Manager of Alchemy Capital, LLC (“Alchemy”) and Trilogy Capital, LLC (“Trilogy”).

Alchemy’s principal business is investments. Alchemy is a Delaware limited liability company.

Trilogy’s principal business is investments. Trilogy is a Delaware limited liability company.

During the last five years, none of the Reporting Persons has been: (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors); or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities, subject to, U.S. federal or state securities laws or finding any violation with respect to such laws.

Pursuant to a Securities Purchase Agreement between the Issuer and Trilogy (“Purchase Agreement”), on April 23, 2020, Trilogy purchased 11,750,000 restricted shares of Common Stock for $94,000. The funds used to purchase Issuer’s shares were from the working capital of Trilogy.

Pursuant to an Exchange Agreement between the Issuer and Trilogy (“Exchange Agreement”), on May 13, 2020, the Issuer purchased from Trilogy all of the capital stock of GPS Associates, Inc. in exchange for 215,250,000 restricted shares of the Issuer of which 19,250,000 shares are to be distributed to certain unaffiliated third parties, including the shareholders of GPS Associates, Inc. Trilogy had previously purchased the capital stock of GPS Associates, Inc.

The information set forth in Item 3, above, is incorporated herein by reference. The Reporting Persons intend to use Issuer to make additional acquisitions, enter into strategic transactions, and/or internally grow the business of the Issuer, although no binding agreements have been entered into as of the date hereof.

The information set forth in Item 4, above, is incorporated herein by reference.

(a)       Alchemy is the record owner of 53,727,273 shares of the Issuer’s Common Stock representing 11.92% of the Company’s outstanding Common Stock. Trilogy is the record owner of 207,750,000 shares of the Issuer’s Common Stock representing 46.11% of the Issuer’s Common Stock. Judy Pham is the sole member and manager of Alchemy and Trilogy, and as such, is the beneficial owner of an aggregate of 261,477,273 shares of the outstanding Common Stock..

(b)       As a result of Dr. Pham’s ownership of Alchemy and Trilogy, Dr. Pham is deemed to have the sole power to vote or direct the vote or to dispose or direct the disposition of all of the shares. Trilogy, as record owner, has shared voting power and shared dispositive power of 207,750,000 shares. Alchemy, as record holder, has shared voting power and shared dispositive power over 53,727,273 shares.

(c)       Pursuant to the Purchase Agreement, on April 23, 2020, Trilogy acquired 11,750,000 shares of the Company’s Common Stock, and on May 13, 2020, pursuant to the Exchange Agreement, Trilogy acquired an additional 196,000,000 shares.

Except as described in this Report, no person has the power to direct the receipt of dividends on, or proceeds of sales of, the shares of Common Stock owned beneficially by the Reporting Persons.

Other than as described in Item 4, above, which information is incorporated herein by reference, there are no contracts, arrangements, understandings or relationships between the Reporting Persons and any other person with respect to the securities of the Issuer.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Mountain High Acquisitions (PK) (USOTC:MYHI)
Historical Stock Chart
From Dec 2020 to Jan 2021

Mountain High Acquisitions (PK) (USOTC:MYHI)
Historical Stock Chart
From Jan 2020 to Jan 2021